Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John J Densmore

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Advances in Hematology & Oncology : H&O|March 19, 2008
Inherited and acquired hematologic disorders in athletesJohn J Densmore
Current Hematology Reports|October 22, 2004
Pegfilgrastim use during chemotherapy: current and future applicationsTodd Wolf, John J Densmore
Current Treatment Options in Oncology|August 29, 2003
Mantle cell lymphomaJohn J Densmore, Michael E Williams
Clinics in Sports Medicine|July 12, 2005
Hematologic disorders in the athleteKelly W Mercer, John J Densmore
Current Opinion in Oncology|August 12, 2005
Biology and therapy of mantle cell lymphomaMichael E Williams, John J Densmore
Expert Opinion on Pharmacotherapy|April 15, 2009
Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphomaMark Prichard, Thomas Harris, Michael E Williams, et al.
Journal of Clinical Trials|December 23, 2014
Gentle Massage Improves Disease- and Treatment-Related Symptoms in Patients with Acute Myelogenous LeukemiaAnn Gill Taylor, Audrey E Snyder, Joel G Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemiaAdam D Kennedy, Paul V Beum, Michael D Solga, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemiaMichael E Williams, John J Densmore, Andrew W Pawluczkowycz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responsesCharles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Advances in Hematology & Oncology : H&O|March 19, 2008
Inherited and acquired hematologic disorders in athletesJohn J Densmore
Current Hematology Reports|October 22, 2004
Pegfilgrastim use during chemotherapy: current and future applicationsTodd Wolf, John J Densmore
Current Treatment Options in Oncology|August 29, 2003
Mantle cell lymphomaJohn J Densmore, Michael E Williams
Clinics in Sports Medicine|July 12, 2005
Hematologic disorders in the athleteKelly W Mercer, John J Densmore
Current Opinion in Oncology|August 12, 2005
Biology and therapy of mantle cell lymphomaMichael E Williams, John J Densmore
Expert Opinion on Pharmacotherapy|April 15, 2009
Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphomaMark Prichard, Thomas Harris, Michael E Williams, et al.
Journal of Clinical Trials|December 23, 2014
Gentle Massage Improves Disease- and Treatment-Related Symptoms in Patients with Acute Myelogenous LeukemiaAnn Gill Taylor, Audrey E Snyder, Joel G Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2004
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemiaAdam D Kennedy, Paul V Beum, Michael D Solga, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemiaMichael E Williams, John J Densmore, Andrew W Pawluczkowycz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2006
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responsesCharles H Redfern, Troy H Guthrie, Alberto Bessudo, et al.
Pageof 1